Description

ADH-1 trifluoroacetate is an N-cadherin antagonist, which inhibits N-cadherin mediated cell adhesion.–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-Kinase/protease–C24H35F3N8O8S2—-[1]Turley RS, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015 Feb;261(2):368-77|[2]Shintani Y, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008 Jan 1;122(1):71-7.|[3]Li H, et al. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007 Jun;18(5):563-8.–1135237-88-5–684.71–99.74–O=C([C@@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC1=CN=CN1)N2)=O)=O)=O)CSSC[C@H](NC(C)=O)C2=O)N.O=C(O)C(F)(F)F–Cancer–DMSO : ≥ 43 mg/mL|H2O : 33.33 mg/mL (ultrasonic)–Others—-Others–Peptides